



Corporate Action Announcement

Citibank, N.A., acting as sponsored depositary bank, announces the following:

Date:	June 29, 2015	Status: Final
Announcement For:	Ratio Change	
Company Name:	AstraZeneca Plc	
Security Information	Current Information	New Information
Company:	Astrazeneca Plc	
Ticker Symbol:	AZN	
CUSIP:	046353108	
Country:	GB	
Exchange:	NYSE	
Ratio (ADR:ORD):	1:1	2 :1
Ordinary Ticker:	AZN LN	
DTC Eligible:	Yes	
Ordinary ISIN:	GB0009895292	
DR ISIN:	US0463531089	
Custodian:	Citibank London	

Announcement

Notice is hereby given that ADS-to-Share ratio will be changed, effective as of the Effective Date, as follows:

Existing ADS-to-Share Ratio:	1 ADS to 1 Share
New ADS-to-Share Ratio:	2 ADS to 1 Share
Effective Date:	July 27, 2015



No action on the part of Holders or Beneficial Owners is required. Holders of ADSs will be receiving a 100% stock distribution. The books of the Depositary will be closed for ADS cancellations from close of business in New York on July 22, 2015 through the close of business in New York on July 29, 2015,

Interim Accounting Due Bills will be imposed by NYSE for this payment. All cross border local shares into ADR share issuances will be delivered by Citibank to the broker only by DWAC during the interim period from July 24, 2015 to July 29, 2015.

Shareholder Services

Questions may be directed to Shareholder Services toll free at 1-888-697-8018.

For further information on Citi Depositary Receipt Services, visit <u>www.citi.com/dr</u>.

© 2013 Citibank, N.A. All rights reserved. Citi and Arc Design and Citibank are trademarks and service marks of Citigroup Inc. and are used and registered throughout the world. The above information is being provided solely for information purposes by Citi. At the time of publication, this information was believed to be accurate, but Citi makes no representation or warranty as to correctness of the information set forth above. The above information does not constitute a recommendation, solicitation or offer by Citi for the purchase or sale of any securities, nor shall this material be construed in any way as investment or legal advice or a recommendation, reference or endorsement by Citi.